These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 26254394)
41. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108 [TBL] [Abstract][Full Text] [Related]
42. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Yang QY; Shen D; Sai K; Mu YG; Jiang XB; Zhang XH; Chen ZP Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):232-5. PubMed ID: 21575527 [TBL] [Abstract][Full Text] [Related]
43. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. Son MJ; Kim JS; Kim MH; Song HS; Kim JT; Kim H; Shin T; Jeon HJ; Lee DS; Park SY; Kim YJ; Kim JH; Nam DH Int J Oncol; 2006 Jan; 28(1):53-9. PubMed ID: 16327979 [TBL] [Abstract][Full Text] [Related]
44. Phase I trial of temozolomide using an extended continuous oral schedule. Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665 [TBL] [Abstract][Full Text] [Related]
45. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases]. Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381 [TBL] [Abstract][Full Text] [Related]
46. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843 [TBL] [Abstract][Full Text] [Related]
47. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856 [TBL] [Abstract][Full Text] [Related]
50. [Combination Therapy with Radiation, Temozolomide, and Bevacizumab after Partial Tumor Removal in Glioblastoma Patients with Low Performance Status]. Nakao J; Ishikawa E; Matsuda M; Yamamoto T; Takano S; Matsumura A Gan To Kagaku Ryoho; 2017 Jun; 44(6):495-500. PubMed ID: 28698441 [TBL] [Abstract][Full Text] [Related]
51. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. Blonski M; Taillandier L; Herbet G; Maldonado IL; Beauchesne P; Fabbro M; Campello C; Gozé C; Rigau V; Moritz-Gasser S; Kerr C; Rudà R; Soffietti R; Bauchet L; Duffau H J Neurooncol; 2012 Jan; 106(2):353-66. PubMed ID: 21785913 [TBL] [Abstract][Full Text] [Related]
52. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Lupo JM; Molinaro AM; Essock-Burns E; Butowski N; Chang SM; Cha S; Nelson SJ Neuro Oncol; 2016 Jan; 18(1):87-95. PubMed ID: 26206774 [TBL] [Abstract][Full Text] [Related]
53. Angiogenesis factors in gliomas: a new key to tumour therapy? Mentlein R; Held-Feindt J Naturwissenschaften; 2003 Sep; 90(9):385-94. PubMed ID: 14504780 [TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Claes A; Wesseling P; Jeuken J; Maass C; Heerschap A; Leenders WP Mol Cancer Ther; 2008 Jan; 7(1):71-8. PubMed ID: 18187807 [TBL] [Abstract][Full Text] [Related]
55. The effects of sequential treatments on hippocampal volumes in malignant glioma patients. Nolen SC; Lee B; Shantharam S; Yu HJ; Su L; Billimek J; Bota DA J Neurooncol; 2016 Sep; 129(3):433-441. PubMed ID: 27393350 [TBL] [Abstract][Full Text] [Related]
56. Update on anti-angiogenic treatment for malignant gliomas. de Groot JF; Mandel JJ Curr Oncol Rep; 2014 Apr; 16(4):380. PubMed ID: 24510742 [TBL] [Abstract][Full Text] [Related]
58. Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma. Lobo MR; Green SC; Schabel MC; Gillespie GY; Woltjer RL; Pike MM Neuro Oncol; 2013 Dec; 15(12):1673-83. PubMed ID: 24092859 [TBL] [Abstract][Full Text] [Related]
59. A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design. Kapoor S; Rallabandi VP; Sakode C; Padhi R; Roy PK Theor Biol Med Model; 2013 Dec; 10():68. PubMed ID: 24369857 [TBL] [Abstract][Full Text] [Related]
60. Cilengitide treatment for malignant glioma: current status and future direction. Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]